Chad Tang1, Kenneth Hess2, Andrew J Bishop1, Hubert Y Pan1, Eva N Christensen1, James N Yang3, Nizar Tannir4, Behrang Amini5, Claudio Tatsui6, Laurence Rhines6, Paul Brown1, Amol Ghia7. 1. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas. 3. Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, Texas. 4. Department of Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 5. Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 6. Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas. 7. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: ajghia@mdanderson.org.
Abstract
PURPOSE: There exists uncertainty in the prognosis of patients following spinal metastasis treatment. We sought to create a scoring system that stratifies patients based on overall survival. METHODS AND MATERIALS: Patients enrolled in 2 prospective trials investigating stereotactic spine radiation surgery (SSRS) for spinal metastasis with ≥ 3-year follow-up were analyzed. A multivariate Cox regression model was used to create a survival model. Pretreatment variables included were race, sex, age, performance status, tumor histology, extent of vertebrae involvement, previous therapy at the SSRS site, disease burden, and timing of diagnosis and metastasis. Four survival groups were generated based on the model-derived survival score. RESULTS: Median follow-up in the 206 patients included in this analysis was 70 months (range: 37-133 months). Seven variables were selected: female sex (hazard ratio [HR] = 0.7, P=.02), Karnofsky performance score (HR = 0.8 per 10-point increase above 60, P = .007), previous surgery at the SSRS site (HR = 0.7, P=.02), previous radiation at the SSRS site (HR = 1.8, P=.001), the SSRS site as the only site of metastatic disease (HR = 0.5, P=.01), number of organ systems involved outside of bone (HR = 1.4 per involved system, P<.001), and >5 year interval from initial diagnosis to detection of spine metastasis (HR = 0.5, P < .001). The median survival among all patients was 25.5 months and was significantly different among survival groups (in group 1 [excellent prognosis], median survival was not reached; group 2 reached 32.4 months; group 3 reached 22.2 months; and group 4 [poor prognosis] reached 9.1 months; P < .001). Pretreatment symptom burden was significantly higher in the patient group with poor survival than in the group with excellent survival (all metrics, P < .05). CONCLUSIONS: We developed the prognostic index for spinal metastases (PRISM) model, a new model that identified patient subgroups with poor and excellent prognoses.
PURPOSE: There exists uncertainty in the prognosis of patients following spinal metastasis treatment. We sought to create a scoring system that stratifies patients based on overall survival. METHODS AND MATERIALS: Patients enrolled in 2 prospective trials investigating stereotactic spine radiation surgery (SSRS) for spinal metastasis with ≥ 3-year follow-up were analyzed. A multivariate Cox regression model was used to create a survival model. Pretreatment variables included were race, sex, age, performance status, tumor histology, extent of vertebrae involvement, previous therapy at the SSRS site, disease burden, and timing of diagnosis and metastasis. Four survival groups were generated based on the model-derived survival score. RESULTS: Median follow-up in the 206 patients included in this analysis was 70 months (range: 37-133 months). Seven variables were selected: female sex (hazard ratio [HR] = 0.7, P=.02), Karnofsky performance score (HR = 0.8 per 10-point increase above 60, P = .007), previous surgery at the SSRS site (HR = 0.7, P=.02), previous radiation at the SSRS site (HR = 1.8, P=.001), the SSRS site as the only site of metastatic disease (HR = 0.5, P=.01), number of organ systems involved outside of bone (HR = 1.4 per involved system, P<.001), and >5 year interval from initial diagnosis to detection of spine metastasis (HR = 0.5, P < .001). The median survival among all patients was 25.5 months and was significantly different among survival groups (in group 1 [excellent prognosis], median survival was not reached; group 2 reached 32.4 months; group 3 reached 22.2 months; and group 4 [poor prognosis] reached 9.1 months; P < .001). Pretreatment symptom burden was significantly higher in the patient group with poor survival than in the group with excellent survival (all metrics, P < .05). CONCLUSIONS: We developed the prognostic index for spinal metastases (PRISM) model, a new model that identified patient subgroups with poor and excellent prognoses.
Authors: Franziska Eckert; Ivan Jelas; Moritz Oehme; Stephan M Huber; Katja Sonntag; Christian Welker; Stephen D Gillies; Wolfgang Strittmatter; Daniel Zips; Rupert Handgretinger; Karin Schilbach Journal: Oncoimmunology Date: 2017-04-28 Impact factor: 8.110
Authors: Garrett Jensen; Chad Tang; Kenneth R Hess; Andrew J Bishop; Hubert Y Pan; Jing Li; James N Yang; Nizar M Tannir; Behrang Amini; Claudio Tatsui; Laurence Rhines; Paul D Brown; Amol J Ghia Journal: J Radiosurg SBRT Date: 2017
Authors: Elie Massaad; Nida Fatima; Muhamed Hadzipasic; Christopher Alvarez-Breckenridge; Ganesh M Shankar; John H Shin Journal: Neurospine Date: 2019-12-31